SCHEMBL31319331

SCHEMBL31319331

Cc1cc(-c2ccc(C#N)cc2-c2ncc[nH]2)cc(Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.48
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
CYP11B2 P19099 3/20 0.37
CYP19A1 P11511 2/20 0.37
CYP11B1 P15538 2/20 0.37
NISCH Q9Y2I1 1/20 0.35
GRM5 P41594 1/20 0.35
PKN1 Q16512 1/20 0.34
PKN2 Q16513 1/20 0.34
LRRK2 Q5S007 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31319197 0.82 CYP11B1 (0.37) ADORA2AHCRTR1HCRTR2CYP11B2CYP19A1
SCHEMBL31319346 0.78 MYC (0.41) ADORA2ACYP11B2CYP11B1GRM5KDM4E
SCHEMBL31319359 0.74 CHEK1 (0.37) HCRTR1HCRTR2NISCHPDE4APDE4B
SCHEMBL31015594 0.73 ADORA2A (0.40) ADORA2ACYP11B2CYP11B1
SCHEMBL31319278 0.73 ADORA2A (0.46) ADORA2ACYP11B2CYP11B1GRM5KDM4E
SCHEMBL31015691 0.72 ADORA2A (0.40) ADORA2ACYP11B2CYP11B1KDM4EALDH1A1
SCHEMBL31015721 0.72 EIF4E (0.49) ADORA2AHCRTR1HCRTR2ALDH1A1
SCHEMBL31015643 0.72 ADORA2A (0.45) ADORA2AHCRTR1HCRTR2CYP11B2GRM5
SCHEMBL31486076 0.71 CYP19A1 (0.45) HCRTR1HCRTR2CYP11B2CYP19A1CYP11B1
SCHEMBL8535598 0.69 CYP19A1 (0.46) ADORA2AHCRTR1HCRTR2CYP11B2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720055-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-04-08 EP disclosed
US-20250011318-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-01-09 US disclosed
WO-2024243502-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011318-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC ADORA2A 4281/4885HCRTR1 4726/4885HCRTR2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.